- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00996853
Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom (H1N1 PASS UK)
Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom (UK)
The focus of this study is to assess the safety of GSK's H1N1 vaccine in real life conditions as soon as the vaccine is used, in a mass vaccination programme, and with a system for rapid generation, communication and evaluation of safety data.
This study is a commitment to the European Medicines Agency (EMEA), as part of GlaxoSmithKline Biologicals' (GSK Biologicals') risk management plan for pandemic influenza vaccination.
Panoramica dello studio
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Addlestone,Surrey, Regno Unito, KT15 2BH
- GSK Investigational Site
-
Attleborough, Norfolk, Regno Unito, NR17 2AS
- GSK Investigational Site
-
Axbridge, Somerset, Regno Unito, BS26 2BJ
- GSK Investigational Site
-
Baldock, Herts, Regno Unito, SG7 6BP
- GSK Investigational Site
-
Balham, London, Regno Unito, SW12 8WU
- GSK Investigational Site
-
Bath, Avon, Regno Unito, BA2 4JT
- GSK Investigational Site
-
Bath, Somerset, Regno Unito, BA2 4BY
- GSK Investigational Site
-
Bedwell Crescent, Stevenage, Regno Unito, SG1 1LQ
- GSK Investigational Site
-
Blenheim Walk, Leeds, Regno Unito, LS2 9AE
- GSK Investigational Site
-
Botesdale, Regno Unito, IP22 1DW
- GSK Investigational Site
-
Boughton, King's Lynn, Regno Unito, PE33 9AG
- GSK Investigational Site
-
Bristol, Avon, Regno Unito, BS13 8LD
- GSK Investigational Site
-
Bromsgrove,Worcestershire, Regno Unito, B61 8DT
- GSK Investigational Site
-
Chard, Somerset, Regno Unito, TA20 1QF
- GSK Investigational Site
-
Chesterfield, Regno Unito, S41 8NA
- GSK Investigational Site
-
Colchester,Essex, Regno Unito, CO4 9YN
- GSK Investigational Site
-
Comberton,Cambridge, Regno Unito, CB23 7DY
- GSK Investigational Site
-
Darlington, Co. Durham, Regno Unito, DL3 8SQ
- GSK Investigational Site
-
Devon, Regno Unito, EX9 6LS
- GSK Investigational Site
-
Didcot,Oxfordshire, Regno Unito, OX11 7JH
- GSK Investigational Site
-
Doncaster, Regno Unito, DN9 1EP
- GSK Investigational Site
-
Ecclesfield, Regno Unito, S35 9XQ
- GSK Investigational Site
-
Ellesmere Port,Cheshire, Regno Unito, CH66 2WW
- GSK Investigational Site
-
Escrick, York, Regno Unito, YO19 6LE
- GSK Investigational Site
-
Essex, Regno Unito, CO3 4LN
- GSK Investigational Site
-
Fleetwood, Regno Unito, FY7 6HD
- GSK Investigational Site
-
Gosport, Regno Unito, PO12 3AQ
- GSK Investigational Site
-
Hanworth, Feltham, Regno Unito, TW13 6HD
- GSK Investigational Site
-
Harrogate, Regno Unito, HG3 5AT
- GSK Investigational Site
-
Harwood, Bolton, Regno Unito, BL2 3HQ
- GSK Investigational Site
-
Hertfordshire, Regno Unito, SG6 4TS
- GSK Investigational Site
-
High Kelling,Holt,Norfolk, Regno Unito, NR25 6QA
- GSK Investigational Site
-
Honiton,Devon, Regno Unito, EX14 2NY
- GSK Investigational Site
-
Hoyland, Barnsley, Regno Unito, S74 9AF
- GSK Investigational Site
-
Hurstpierpoint, West Sussex, Regno Unito, BN6 9UQ
- GSK Investigational Site
-
Kent, Sevenoaks, Regno Unito, TN13 3NT
- GSK Investigational Site
-
Kettering,Kettering, Regno Unito, NN14 1SN
- GSK Investigational Site
-
Kippax,Leeds, Regno Unito, LS25 7JN
- GSK Investigational Site
-
Lambeth, London, Regno Unito, SW16 5LS
- GSK Investigational Site
-
Lancashire, Regno Unito, BL1 6AP
- GSK Investigational Site
-
Lancaster, Regno Unito, LA1 1RP
- GSK Investigational Site
-
Langport, Somerset, Regno Unito, TA10 9RH
- GSK Investigational Site
-
Leicester, Regno Unito, LE4 0UZ
- GSK Investigational Site
-
Lichfield, Regno Unito, WS13 6JL
- GSK Investigational Site
-
London, Regno Unito, NW3 1NR
- GSK Investigational Site
-
London, Regno Unito, SE11 6SP
- GSK Investigational Site
-
London, Regno Unito, W11 1PA
- GSK Investigational Site
-
Lutterworth, Leicestershire, Regno Unito, LE17 4EB
- GSK Investigational Site
-
Mossley, Ashton Under Lyne, Regno Unito, OL5 0HE
- GSK Investigational Site
-
Nantwich, Cheshire, Regno Unito, CW5 5NX
- GSK Investigational Site
-
Norwich, Norfolk, Regno Unito, NR12 8DU
- GSK Investigational Site
-
Norwich, Norfolk, Regno Unito, NR3 2HW
- GSK Investigational Site
-
Nottingham, Regno Unito, NG7 2QW
- GSK Investigational Site
-
Orton Goldhay, Peterborough, Regno Unito, PE2 5GP
- GSK Investigational Site
-
Oxfordshire, Regno Unito, OX12 9BN
- GSK Investigational Site
-
Paiginton, Devon, Regno Unito, TQ3 3TB
- GSK Investigational Site
-
Radstock, Bath, Regno Unito, BA3 2UH
- GSK Investigational Site
-
Romsey, Hampshire, Regno Unito, SO517QN
- GSK Investigational Site
-
Rowlands Castle, Regno Unito, PO9 6BN
- GSK Investigational Site
-
Ruislip, Regno Unito, HA4 6ER
- GSK Investigational Site
-
Runcorn, Cheshire, Regno Unito, WA7 1AB
- GSK Investigational Site
-
Salisbury, Hampshire, Regno Unito, SP1 1DX
- GSK Investigational Site
-
Sedgefield, Regno Unito, TS21 3BN
- GSK Investigational Site
-
Shipston-on-Stour, Warwickshire, Regno Unito, CV36 4BQ
- GSK Investigational Site
-
Somerset, Regno Unito, TA18 8BX
- GSK Investigational Site
-
Southbourne, Hampshire, Regno Unito, PO10 8JH
- GSK Investigational Site
-
Southsea, Hampshire, Regno Unito, P05 3ND
- GSK Investigational Site
-
Stowmarket,Suffolk, Regno Unito, IP14 1NL
- GSK Investigational Site
-
Sunderland, Regno Unito, SR3 4HG
- GSK Investigational Site
-
Sway, Hampshire, Regno Unito, S041 6BA
- GSK Investigational Site
-
Swindon, Wiltshire, Regno Unito, SN25 1QQ
- GSK Investigational Site
-
Tadworth,Surrey, Regno Unito, KT20 5JE
- GSK Investigational Site
-
Tarporley,Cheshire, Regno Unito, CW6 0BE
- GSK Investigational Site
-
Thornbury, Bristol, Regno Unito, BS35 1DP
- GSK Investigational Site
-
Wandsford, Peterborough, Regno Unito, PE8 6PL
- GSK Investigational Site
-
Wantage, Regno Unito, OX12 9BN
- GSK Investigational Site
-
Wantage, Oxon, Regno Unito, OX12 9BN
- GSK Investigational Site
-
Western Approach,Plymouth, Regno Unito, PL1 5AJ
- GSK Investigational Site
-
Westhoughton, Bolton, Regno Unito, BL5 3UB
- GSK Investigational Site
-
Wiltshire, Regno Unito, SN10 4AQ
- GSK Investigational Site
-
Wiltshire, Westbury, Regno Unito, BA13 3JD
- GSK Investigational Site
-
Windemere,Cumbria, Regno Unito, LA23 2EG
- GSK Investigational Site
-
Wokingham, Berkshire, Regno Unito, RG41 3DR
- GSK Investigational Site
-
York, Regno Unito, YO24 4HD
- GSK Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Regno Unito, CB3 9HS
- GSK Investigational Site
-
-
Hertfordshire
-
Watford, Hertfordshire, Regno Unito, WD25 0EA
- GSK Investigational Site
-
-
Kent
-
Canterbury, Kent, Regno Unito, CT1 3HX
- GSK Investigational Site
-
-
Lancashire
-
Blackburn, Lancashire, Regno Unito, BB2 2ST
- GSK Investigational Site
-
-
Northamptonshire
-
Wellingborough, Northamptonshire, Regno Unito, NN8 4RW
- GSK Investigational Site
-
-
Somerset
-
Bath, Somerset, Regno Unito, BA2 1NH
- GSK Investigational Site
-
Frome, Somerset, Regno Unito, BA11 1EZ
- GSK Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Written informed consent, and assent where appropriate, obtained from the subject/from the subject's parent(s)/ Legally Acceptable Representative(s) (LAR).
- A male or female subject vaccinated with a first dose of GSK Biologicals' H1N1 pandemic influenza vaccine
- shortly (<24h) before being recruited in the study, and
- within a GP practice participating in the study and where the subject is registered.
- Subjects who the Investigator believes that they and/or their parent(s)/LAR can and will comply with the requirements of the protocol
Exclusion Criteria:
- Subjects already vaccinated with any other H1N1 pandemic vaccine before study enrolment.
- Child in care
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Total vaccinated cohort
The Total vaccinated cohort will include all subjects with at least one vaccine administration documented.
|
Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Medically-attended adverse events
Lasso di tempo: Within one month after any dose
|
Within one month after any dose
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Adverse events solicited to assess reactogenicity
Lasso di tempo: Within seven days after any dose
|
Within seven days after any dose
|
Serious adverse events and adverse events of special interest
Lasso di tempo: Within six months after the second vaccine dose or within a maximum of eight months after the first dose
|
Within six months after the second vaccine dose or within a maximum of eight months after the first dose
|
Pregnancy outcomes
Lasso di tempo: Within two months after vaccination (last menstrual period up to 45 days after any dose)
|
Within two months after vaccination (last menstrual period up to 45 days after any dose)
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Nazareth I, Tavares F, Rosillon D, Haguinet F, Bauchau V. Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study. BMJ Open. 2013 Feb 5;3(2):e001912. doi: 10.1136/bmjopen-2012-001912. Print 2013. Erratum In: BMJ Open. 2013 Feb 19;3(2):null.
- Tavares F, Nazareth I, Monegal JS, Kolte I, Verstraeten T, Bauchau V. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. Vaccine. 2011 Aug 26;29(37):6358-65. doi: 10.1016/j.vaccine.2011.04.114. Epub 2011 May 17.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 113585
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Safety follow up
-
Nantes University HospitalSconosciutoInsufficienza renaleFrancia
-
University of UtahStanford UniversityCompletato
-
Zealand University HospitalNon ancora reclutamentoAdenoma ipofisario non funzionale
-
University of California, Los AngelesPatient-Centered Outcomes Research Institute; Brown University; Duke University; University... e altri collaboratoriReclutamentoSuicidio e autolesionismoStati Uniti
-
Second Affiliated Hospital, School of Medicine,...First Affiliated Hospital of Wenzhou Medical University; Jinhua Central Hospital e altri collaboratoriReclutamentoDisfunsione dell'arteria coronariaCina
-
Air Liquide Healthcare SpainHospital Universitari Joan XXIII de Tarragona.; Fundación de Investigación Biomédica...CompletatoApnea notturna, ostruttivaSpagna
-
Dana-Farber Cancer InstituteCompletatoCancro al seno | Cancro alla prostata | Coinvolgimento del paziente | Soddisfazione del paziente | Preferenza del pazienteStati Uniti
-
Pontificia Universidad Catolica de ChileUniversity of Technology, SydneyCompletatoMalattia cardiovascolare | Ipertensione | Diabete mellito di tipo 2 | Dislipidemie | Aderenza ai farmaci | Uso di drogaChile
-
Norwegian University of Science and TechnologyHelse Stavanger HF; St. Olavs Hospital; Sykehuset Innlandet HF; Alesund Hospital; Molde... e altri collaboratoriCompletato